UroLift, also called prostatic urethral lift (PUL), is a minimally invasive treatment for urinary obstruction associated with BPH and prostate enlargement. Instead of cutting, vaporizing or removing prostate tissue, small permanent implants retract selected prostate tissue away from the urethra to create a wider urinary channel.
01. UroLift: Indications, Technique and Treatment Role
What problem is UroLift intended to treat?
UroLift is intended to reduce resistance to urine flow when enlarged prostate tissue narrows the outlet from the bladder.
The anatomical problem occurs because the prostate surrounds the first part of the urethra. This segment is called the prostatic urethra. As prostate tissue enlarges inward, the available lumen for urine can become narrower.
Understanding this relationship is part of the wider prostate health and prostate anatomy pathway.
When benign enlargement contributes to bladder-outlet resistance, men may experience:
- a weak urinary stream;
- difficulty starting urination;
- intermittent flow;
- straining;
- incomplete emptying;
- urgency or frequency;
- or other bothersome lower urinary tract symptoms.
Unlike HoLEP or TURP, UroLift does not create a large surgical cavity and does not intentionally destroy the treated prostate tissue.
What happens before and during UroLift?
Patient selection begins with assessment of symptoms, urinary flow, bladder emptying and prostate anatomy.
Prostate size can influence whether PUL is appropriate. The measurement process is explained in how prostate volume is measured.
The presence and configuration of a middle or median lobe can also influence treatment planning. FBU explains this anatomy separately in median lobe prostate enlargement and intravesical prostatic protrusion.
During UroLift, a delivery instrument is passed through the urethra under cystoscopic guidance. The device compresses selected prostate tissue and deploys small implants that maintain the tissue in a retracted position.
02. How Is UroLift Performed?
How does a prostatic urethral lift implant hold prostate tissue open?
The implant works by connecting the urethral side of the prostate to an anchor positioned toward the outer prostate.
Tension between these components compresses the intervening prostate tissue. Multiple implants can be placed at selected locations to create an open anterior channel through the prostatic urethra.
Which anatomy, prostate size or disease factors affect UroLift?
Prostate morphology is particularly important for PUL because the implants must be positioned where retracting tissue will meaningfully increase the urethral opening.
The strongest randomized evidence behind current European recommendations comes from men with glands below approximately 70 mL and without an obstructing middle lobe.
American guideline recommendations are also based mainly on appropriately selected glands in approximately the 30–80 g range without an obstructive middle lobe.
Current U.S. device labeling is broader and permits treatment of symptoms associated with lateral or median-lobe hyperplasia in prostates up to 100 cc. This difference is important: a regulatory indication and the population with the strongest guideline-level comparative evidence are not identical.
Because anatomy influences treatment selection, a clinician may assess prostate volume, median-lobe configuration and bladder outlet anatomy before recommending the procedure.
What are the main expected outcomes after UroLift?
Prostatic urethral lift can produce clinically meaningful improvement in urinary symptoms, quality of life and maximum urinary flow.
EAU evidence summaries report improvements in symptom scores, flow and quality of life after PUL, but the average improvement is smaller than after TURP.
This does not mean PUL is an ineffective procedure. Its value is based on a different balance of outcomes: less tissue disruption, relatively rapid recovery and a favorable sexual-function profile in exchange for less powerful objective decompression and a greater probability of additional treatment later.
03. UroLift: Outcomes, Recovery and Procedure-Specific Trade-Offs
What does recovery after UroLift usually involve?
UroLift can often be performed as an outpatient procedure using local, regional or general anesthesia depending on the patient, center and treatment plan.
Because no prostate tissue is intentionally resected, vaporized or thermally destroyed, recovery is often faster than after conventional tissue-removing surgery.
Common temporary effects include:
- burning or discomfort during urination;
- blood in the urine;
- pelvic discomfort;
- urinary urgency;
- increased urinary frequency;
- temporary difficulty urinating;
- and occasionally urinary tract infection.
Most early adverse effects are mild to moderate and commonly settle during the first several weeks.
Some men urinate without a catheter immediately after treatment, while others require temporary catheter drainage because of swelling, pre-existing retention or difficulty emptying the bladder.
Which urinary or sexual effects should be discussed before UroLift?
One of the main reasons men consider UroLift is its favorable sexual-function profile.
Unlike operations that remove tissue around the bladder neck and prostatic urethra, PUL generally has a low incidence of new sustained ejaculatory dysfunction in appropriately selected men.
Erectile function is also generally preserved.
However, “ejaculation preserving” should not be interpreted as a guarantee that every individual will experience no sexual change. Baseline sexual function, other medical conditions, medicines and individual procedural outcomes still matter.
How durable is UroLift?
Symptom improvement can remain clinically meaningful for years, but UroLift is generally less durable than established tissue-removing procedures.
In the multicenter L.I.F.T. study, approximately 13.6% of treated patients underwent surgical retreatment over five years.
EAU guidance therefore recommends explicitly discussing the higher likelihood of retreatment compared with TURP.
Retreatment can involve another PUL procedure or a different surgical or laser technique depending on the recurrent obstruction, anatomy and patient goals.
04. Who Is Most Likely to Be Considered for UroLift?
How does UroLift compare with tissue-removing BPH surgery?
UroLift and tissue-removing procedures solve the outlet problem differently.
The preceding FBU procedure, HoLEP for BPH, enucleates enlarged adenoma. UroLift leaves the prostate tissue in place and mechanically retracts selected areas instead.
| Feature | UroLift / PUL | Tissue-removing surgery |
|---|---|---|
| Tissue removal | No intentional resection, vaporization or enucleation. | Obstructing prostate tissue is physically removed or destroyed. |
| Urinary improvement | Meaningful improvement, but generally less than TURP. | Usually greater improvement in flow and obstruction. |
| Recovery | Usually relatively rapid. | Often requires a longer postoperative recovery period. |
| Catheter | Not required in every patient. | Temporary catheterization is common after many operations. |
| Ejaculation | Low incidence of new sustained ejaculatory dysfunction. | Standard TURP and HoLEP frequently alter ejaculation. |
| Durability | Higher probability of later retreatment. | Generally stronger long-term durability. |
| Best fit | Selected patients prioritizing recovery and sexual-function preservation. | Patients prioritizing stronger or more definitive outlet decompression. |
When may UroLift be unsuitable or require additional evaluation?
PUL may be less suitable when the prostate is very large, when anatomy cannot be adequately opened with implant placement, when urinary retention or severe obstruction requires more powerful decompression, or when another procedure better matches the patient’s goals.
The distinction between prostate size and actual obstruction is important. FBU discusses this separately in how prostate size relates to BPH symptoms and obstruction.
A weak urinary stream or incomplete emptying also does not automatically prove that the prostate is the only problem. Poor bladder contraction, urethral narrowing and other urinary disorders can produce similar findings.
The wider relationship between prostate growth, symptoms, obstruction, diagnosis and treatment is covered in the BPH and enlarged prostate guide.
How should the median-lobe evidence be interpreted?
This is an area where the wording needs to be precise.
Current European guideline recommendations for UroLift are based mainly on patients with prostates below 70 mL and without an obstructing middle lobe. The AUA evidence base also centers on glands below 80 g without an obstructive middle lobe.
However, current U.S. UroLift device labeling includes lateral and median-lobe hyperplasia and allows treatment of prostates up to 100 cc.
Therefore, the presence of a median lobe should not simply be described as an absolute modern contraindication to every UroLift procedure. Instead, it is an anatomical feature that requires careful evaluation because the strength of comparative guideline evidence differs by anatomy.
Summary
- UroLift is also called prostatic urethral lift or PUL.
- It relieves obstruction by retracting selected prostate tissue away from the prostatic urethra.
- The procedure does not intentionally cut, vaporize, enucleate or remove prostate tissue.
- Its strongest advantages are relatively rapid recovery and a low incidence of new sustained erectile or ejaculatory dysfunction.
- Urinary symptoms, urinary flow and quality of life can improve substantially, although average objective improvement is less than after TURP.
- Prostate volume and the distribution of lateral or median-lobe tissue are important during patient selection.
- Current European guideline recommendations are strongest for prostates below 70 mL without a middle lobe, while current U.S. device labeling permits broader anatomy and prostates up to 100 cc.
- Temporary dysuria, hematuria, pelvic discomfort, urgency and urinary difficulty may occur during early recovery.
- Retreatment is more common after PUL than after TURP; five-year trial data reported a surgical retreatment rate of about 13.6%.
- There is no universally best BPH procedure. Treatment choice depends on anatomy, obstruction severity, recovery goals, sexual priorities and desired durability.
Educational disclaimer: This article provides general medical education and does not recommend UroLift or another procedure for an individual. Appropriate treatment requires evaluation of urinary symptoms, prostate anatomy, prostate volume, bladder function, medical risk and patient priorities by a qualified clinician.
Explore the Prostate and BPH Pathway
The anatomy behind prostatic urethral lift can be explored through Prostate Health, Prostate Anatomy and Function, and the Prostatic Urethra guide.
For treatment context, continue through BPH and Enlarged Prostate and the BPH Surgery and Minimally Invasive Procedures guide.
Evidence Sources
- European Association of Urology. Management of Non-neurogenic Male LUTS: Prostatic Urethral Lift.
- American Urological Association. Management of Lower Urinary Tract Symptoms Attributed to Benign Prostatic Hyperplasia.
- U.S. Food and Drug Administration. UroLift System 510(k) Summary — Indications and Contraindications.
